SLC5A2 and familial dilated cardiomyopathy: As demonstrated by the results of the EMPA-REG OUTCOMES trial, SGLT-2 inhibitors show great potential cardioprotective effects in improving DCM and anti-inflammatory properties, regardless of hypoglycemic capability [142].